Andrew Huberman· PhD
Instead, we look at modifying 10-year risk. So that's the fundamental difference between what I call medicine 2.0 and medicine 3.0. Medicine 2.0, which is what we're generally practicing today, when it comes to ASCVD says, look, we will treat you, we will lower that LDL cholesterol, they still don't talk about ApoB, but that's a very American thing.